Infliximab Concentrations in Participants with Moderate to Severe COVID-19

the ACTIV-1 Study Team

doi:10.1002/jcph.2388

Infliximab Concentrations in Participants with Moderate to Severe COVID-19

the ACTIV-1 Study Team

Producción científica: Letter › revisión exhaustiva

Idioma original	English (US)
Páginas (desde-hasta)	490-491
Número de páginas	2
Publicación	Journal of Clinical Pharmacology
Volumen	64
N.º	4
DOI	https://doi.org/10.1002/jcph.2388
Estado	Published - abr 2024

ASJC Scopus subject areas

Pharmacology
Pharmacology (medical)

Acceder al documento

10.1002/jcph.2388

Otros archivos y enlaces

Link to publication in Scopus

Citar esto

@article{33252785c7914592a5e0a71d0ef132db,

title = "Infliximab Concentrations in Participants with Moderate to Severe COVID-19",

keywords = "COVID-19, infliximab, pharmacokinetics",

author = "{the ACTIV-1 Study Team} and Balevic, {Stephen J.} and Dima Dandachi and Danielle Dixon and Hoetelmans, {Richard M.W.} and Sam Bozzette and McCarthy, {Matthew W.}",

year = "2024",

month = apr,

doi = "10.1002/jcph.2388",

language = "English (US)",

volume = "64",

pages = "490--491",

journal = "Journal of Clinical Pharmacology",

issn = "0091-2700",

publisher = "Wiley-Blackwell",

number = "4",

}

TY - JOUR

T1 - Infliximab Concentrations in Participants with Moderate to Severe COVID-19

AU - the ACTIV-1 Study Team

AU - Balevic, Stephen J.

AU - Dandachi, Dima

AU - Dixon, Danielle

AU - Hoetelmans, Richard M.W.

AU - Bozzette, Sam

AU - McCarthy, Matthew W.

PY - 2024/4

Y1 - 2024/4

KW - COVID-19

KW - infliximab

KW - pharmacokinetics

UR - http://www.scopus.com/inward/record.url?scp=85179938686&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85179938686&partnerID=8YFLogxK

U2 - 10.1002/jcph.2388

DO - 10.1002/jcph.2388

M3 - Letter

C2 - 38031826

AN - SCOPUS:85179938686

SN - 0091-2700

VL - 64

SP - 490

EP - 491

JO - Journal of Clinical Pharmacology

JF - Journal of Clinical Pharmacology

IS - 4

ER -